Identification of signaling networks associated with lactate modulation of macrophages and dendritic cells by Rapeepat Sangsuwan, Bhasirie Thuamsang, Noah Pacifici, Phum Tachachartvanich, Devan Murphy, Abhineet Ram, John Albeck, Jamal S. Lewis

“…The advancement in the understanding of cancer immune evasion has manifested the development of cancer immunotherapeutic approaches such as checkpoint inhibitors and interleukin agonists. …”
Get full text

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer by Renee Vermeij, Toos Daemen, Geertruida H. de Bock, Pauline de Graeff, Ninke Leffers, Annechien Lambeck, Klaske A. ten Hoor, Harry Hollema, Ate G. J. van der Zee, Hans W. Nijman

“…The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a “universal” vaccine strategy. …”
Get full text

Interleukin-6 as a Pan-Cancer Prognostic Inflammatory Biomarker: A Population-Based Study and Comprehensive Bioinformatics Analysis by Xie H, Wei L, Ruan G, Zhang H, Shi H

“…This study aimed to provide a comprehensive assessment of the prognostic value of IL-6 and its immunotherapeutic features using a population-based pan-cancer analysis and comprehensive bioinformatic analysis.Patients and Methods: In the cohort study, 540 patients were included to explore the prognostic value of serum IL-6 levels in cancer. …”
Get full text

Analysis and Validation of Autophagy-Related Gene Biomarkers and Immune Cell Infiltration Characteristic in Bronchopulmonary Dysplasia by Integrating Bioinformatics and Machine Lea... by Xiao S, Ding Y, Du C, Lv Y, Yang S, Zheng Q, Wang Z, Zheng Q, Huang M, Xiao Q, Ren Z, Bi G, Yang J

“…Our findings provided researchers and clinicians with more evidence regarding immunotherapeutic strategies for BPD treatment.Keywords: BPD, autophagy, immune cell infiltration, single cell sequencing, biomarkers…”
Get full text

A panel of cancer testis antigens in squamous cell carcinoma of the lung, head and neck, and esophagus: implication for biomarkers and therapeutic targets by Lin Li, Xin Zhang, Jiayao Yan, Jingyi Guo, Fangcen Liu, Xiao Wei, Qin Liu, Kongcheng Wang, Baorui Liu

“…Abstract This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). …”
Get full text

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment by Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen

“…Mechanistically, OXA upregulated YTHDF2 expression by activating the cGAS-STING signaling pathway and consequently enhanced the therapeutic outcomes of immunotherapeutic interventions. Ythdf2 stabilized Cx3cl1 transcripts in an m6A-dependent manner, regulating the interplay between CD8+ T cells and the progression of liver malignancies. …”
Get full text

Intrinsic PD‐L1 Degradation Induced by a Novel Self‐Assembling Hexapeptide for Enhanced Cancer Immunotherapy by Hongxia Zhang, Ming Ji, Yamei Wang, Mengmeng Jiang, Zongyu Lv, Gongyu Li, Lulu Wang, Zhen Zheng

“…This “carrier‐free” delivery system expands the role of supramolecular hydrogels beyond passive carriers to active immunotherapeutic agents, offering a promising new strategy for cancer therapy.…”
Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

“…ObjectivePD-1/PD-L1 inhibitors are novel immunotherapeutic agents that have been approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). …”
Get full text

Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy by Jian Huang, Shuangna Song, Yihua Yin, Yinyan He, Huimin Wang, Ye Gu, Laman He, Xintao Wang, Xiaocao Miao, Zhigang Zhang, Xueli Zhang, Yiran Li, Yiran Li

“…Importantly, by using an organoid model of EC, we further confirmed the antitumor potential of T cells that were specific to the POLEP286R mutation.ConclusionsOur study uncovers the pronounced immunogenicity of POLE-mutant EC and characterizes neoantigens that are unique to the POLEP286R mutation, thus providing a promising new immunotherapeutic strategy for EC.…”
Get full text

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy by Diana V. Yuzhakova, Daria A. Sachkova, Anna V. Izosimova, Konstantin S. Yashin, Gaukhar M. Yusubalieva, Vladimir P. Baklaushev, Artem M. Mozherov, Vladislav I. Shcheslavskiy, Marina V. Shirmanova

“…Conclusions: The proposed platform that includes tumor explants co-cultured with lymphocytes and the NAD(P)H FLIM assay represents a promising solution for the patient-specific immunotherapeutic drug screening.…”
Get full text

Targeting HVEM-GPT2 axis: a novel approach to T cell activation and metabolic reprogramming in non-small cell lung cancer therapy by Yuanshan Yao, Chunji Chen, Bin Li, Wen Gao

“…Crucially, HVEM, part of the tumor necrosis factor receptor superfamily, influences T cell activation, potentially impacting immunotherapeutic outcomes. Using the TIDE algorithm, our results showcased a link between HVEM levels and immune dysfunction in NSCLC patients. …”
Get full text

Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy by Jian Cheng, Miaomiao Sun, Xiao Dong, Yang Yang, Xiaohan Qin, Xing Zhou, Yongcheng Fu, Yuanyuan Wang, Jingyue Wang, Da Zhang

“…Targeting SLC1A5 through advanced drug delivery systems and combined metabolic-immunotherapeutic strategies may enhance treatment specificity and efficacy. …”
Get full text

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor

“…A ‘best-in-class’ lintuzumab-CD28/CD3ζ CAR construct was thus selected for clinical translation.Conclusions CD33 is a critical antigen for potential immunotherapeutic targeting in patients with AML. Based on this rigorous preclinical evaluation, our validated clinical grade lintuzumab-CD28/CD3ζ CD33CART immunotherapy is now under evaluation in a first-in-child/first-in-human phase 1 clinical trial for children and adolescents/young adults with relapsed/refractory AML.Trial registration number clinicaltrials.gov; NCT03971799.…”
Get full text

Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases by Luca Perico, Federica Casiraghi, Fabiane Sônego, Marta Todeschini, Daniela Corna, Domenico Cerullo, Anna Pezzotta, Patricia Isnard-Petit, Silvia Faravelli, Federico Forneris, Kader Thiam, Ariela Benigni, Giuseppe Remuzzi

“…For this reason, identification of targeted therapies for autoimmune diseases is an unmet clinical need.MethodsHere, we designed a novel class of immunotherapeutic molecules, Bi-specific AutoAntigen-T cell Engagers (BiAATEs), as a potential approach for targeting the small subset of autoreactive B cells. …”
Get full text

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma by Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose, Alyssa S. Mendelowitz, Keira Foley, Mehmet F. Ozkaynak, Wen Luo, Timothy P. Cripe, Dean A. Lee, Kevin A. Cassady, Mitchell S. Cairo

“…Our results suggest that cytokine-secreting oncolytic virus in combination with CAR-NK cells is a novel, effective immunotherapeutic approach for high-risk NB.…”
Get full text

Differential impact of TIM-3 ligands on NK cell function by Xin Zhang, Lazar Vujanovic, Riyue Bao, Robert L Ferris, Tullia C Bruno, Aditi Kulkarni, Hridesh Banerjee, Housaiyin Li, Juncheng Wang, Lawrence P Kane, Pragati Upadhyay, Jennifer L Anderson, Onyedikachi Victor Onyekachi, Lidia M R B Arantes

“…Among patients with HNSCC, an elevated intratumoral TIM-3+ NK cell gene signature associates with worse outcomes, specifically in those with human papillomavirus (HPV)+ disease, potentially attributable to higher galectin-9 levels in HPV+ versus HPV− patients.Conclusions Our findings underscore the complex functional impact of TIM-3 ligand signaling, which is consistent with recent clinical trials suggesting that targeting TIM-3 alone is suboptimal as an immunotherapeutic approach for treating malignancies.…”
Get full text

The emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer by Rachel Pounds, Rachel Pounds, Wayne Croft, Hayden Pearce, Tasnia Hossain, Kavita Singh, Janos Balega, David N. Jeevan, Sudha Sundar, Sudha Sundar, Sean Kehoe, Jason Yap, Jason Yap, Paul Moss, Jianmin Zuo

“…Expression of PVR, the DNAM-1 ligand, was significantly increased on tumours and DNAM-1 mediated NK cell lysis of primary tumour tissue was observed in vitro.DiscussionThese findings reveal profound modulation of the tumour tissue and systemic profile of NK cells which likely contributes to the high rates of local progression and metastasis seen with OC. Immunotherapeutic approaches that overcome local immune suppression and enhance DNAM-1-targeted lysis of OC offer the potential to improve disease control.…”
Get full text

Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis by Xiang Li, Gao He, Hui Jin, Xinyu Xiang, Dong Li, Renmiao Peng, Jing Tao, Xinping Li, Kaiyang Wang, Yu Luo, Xiaoan Liu

“…Additionally, a reactive oxygen species (ROS) sensitive linker is used to attach the immunotherapeutic drug PD‐L1 inhibitor (aPD‐L1) to DMSNs via covalent bonds. …”
Get full text

Machine learning based identification of an amino acid metabolism related signature for predicting prognosis and immune microenvironment in pancreatic cancer by Xiaohong Liu, Xing Wang, Jie Ren, Yuan Fang, Minzhi Gu, Feihan Zhou, Ruiling Xiao, Xiyuan Luo, Jialu Bai, Decheng Jiang, Yuemeng Tang, Bo Ren, Lei You, Yupei Zhao

“…Notably, the risk score from this novel signature showed significant correlations with TMB, drug resistance, as well as a heightened likelihood of immune evasion and suboptimal responses to immunotherapeutic interventions. Conclusion Our findings suggested that amino acid metabolism-related signature was closely related to the development, prognosis and immune microenvironment of pancreatic cancer.…”
Get full text

Serum and Salivary IgE, IgA, and IgG4 Antibodies to Dermatophagoides pteronyssinus and Its Major Allergens, Der p1 and Der p2, in Allergic and Nonallergic Children by Diego O. Miranda, Deise A. O. Silva, Jorge F. C. Fernandes, Meimei G. J. Queirós, Hamilton F. Chiba, Leandro H. Ynoue, Rafael O. Resende, Janethe D. O. Pena, Sun-Sang J. Sung, Gesmar R. S. Segundo, Ernesto A. Taketomi

“…Also, specific IgA measurements in serum and/or saliva may be useful for monitoring activation of tolerance-inducing mechanisms during allergen specific immunotherapeutic procedures, especially sublingual immunotherapy.…”
Get full text